Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04699903 · ClinicalTrials.gov registry record
Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 (COVID-19) IgG Antibody Test in Fingerstick Whole Blood
A clinical trial, sponsored by Lumos Diagnostics.
- Completed
- Registry status
- 201
- Enrollment target
NCT04699903: Completed study, sponsored by Lumos Diagnostics.
NCT04699903 is a clinical trial that has completed, run by Lumos Diagnostics. The registered enrollment target is 201 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04699903 has completed, sponsored by Lumos Diagnostics.
- COMPLETED
- Registry status
- 201 participants
- Enrollment target
Study Summary
Prospective, multi-center, observational, blinded clinical trial to compare a new point of care (POC) SARS-CoV-2 IgG antibody test to a reference SARS-CoV-2 PCR test using fingerstick whole blood.
Primary Outcome
Determine PPA and NPA of point of care (POC) SARS-CoV-2 IgG antibody test compared to SARS-CoV-2 PCR with EUA (FDA emergency use authorization)
Interventions
- DIAGNOSTIC_TEST POC SARS-Cov-2 IgG Antibody test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2021-01-05 |
| Est. Completion | 2021-04-09 |
What the finished NCT04699903 record still lists
NCT04699903 is an observational study that tracks outcomes without assigning an intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which POC SARS-Cov-2 IgG Antibody test is the first listed.
NCT04699903 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04699903 about?
NCT04699903 is a clinical study titled "Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 (COVID-19) IgG Antibody Test in Fingerstick Whole Blood". Prospective, multi-center, observational, blinded clinical trial to compare a new point of care (POC) SARS-CoV-2 IgG antibody test to a reference SARS-CoV-2 PCR test using fingerstick whole blood.
What is the current status of trial NCT04699903?
This trial is currently completed. The enrollment target is 201 participants. The study started on 2021-01-05. Estimated completion is 2021-04-09.
What interventions are being tested in trial NCT04699903?
The interventions under investigation include: POC SARS-Cov-2 IgG Antibody test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04699903?
This trial is sponsored by Lumos Diagnostics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04422652 · 201 participants · Phase 2
Combination of Novel Therapies for CKD Comorbid Depression
- NCT05327114 · 201 participants · Phase 2
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- NCT06099769 · 201 participants · Phase 2
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- NCT06274528 · 201 participants · Phase 2
DORA and LP in Alzheimer's Disease Biomarkers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI